PurposeTo compare the rates of hepatotoxicity after transarterial chemoembolization for hepatocellular carcinoma (HCC) in patients with and without a transjugular intrahepatic portosystemic shunt (TIPS) who were stratified into comparable risk groups.Materials and methodsA retrospective review of patients with HCC who were treated with transarterial chemoembolization between January 2005 and December 2009 was performed. Of 158 patients with comparable model for end-stage liver disease (MELD) scores, 10 had a patent TIPS. Hepatobiliary severe adverse events (SAEs) occurring after transarterial chemoembolization were documented. In addition, 1-year survival and liver transplantation rate after transarterial chemoembolization were calculated i...
Purpose: To determine any differences in patient characteristics and outcomes after transarterial ch...
Background: Liver cancer is the second most common cause of cancer-related death, with hepatocellula...
IntroductionThe outcomes of transjugular intrahepatic portosystemic shunt (TIPS) placement in patien...
AbstractBackgroundTransarterial chemoembolization (TACE) for the treatment of hepatocellular carcino...
PURPOSEHepatocellular carcinoma (HCC) usually occurs accompanied by portal hypertension. Transcathet...
PurposeTo compare treatment response after transarterial chemoembolization (TACE) for hepatocellular...
Background: Transarterial chemoembolization (TACE) in patients with hepatocellular cancer (HCC) on t...
PURPOSEWe aimed to investigate the safety and long-term outcomes of repeated transcatheter arterial ...
Introduction: Hepatic transarterial chemoembolization is a widely used technique for the treatment o...
BACKGROUND Transarterial chemoembolization (TACE) in patients with hepatocellular cancer (HCC) on...
To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (c...
Objective: This study aimed to explore the risk factors of hepatocellular carcinoma (HCC) and surviv...
Background: To evaluate the safety and efficacy of transjugular intrahepatic portosystemic shunt (TI...
Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently cause...
Background: An association between Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) and the dev...
Purpose: To determine any differences in patient characteristics and outcomes after transarterial ch...
Background: Liver cancer is the second most common cause of cancer-related death, with hepatocellula...
IntroductionThe outcomes of transjugular intrahepatic portosystemic shunt (TIPS) placement in patien...
AbstractBackgroundTransarterial chemoembolization (TACE) for the treatment of hepatocellular carcino...
PURPOSEHepatocellular carcinoma (HCC) usually occurs accompanied by portal hypertension. Transcathet...
PurposeTo compare treatment response after transarterial chemoembolization (TACE) for hepatocellular...
Background: Transarterial chemoembolization (TACE) in patients with hepatocellular cancer (HCC) on t...
PURPOSEWe aimed to investigate the safety and long-term outcomes of repeated transcatheter arterial ...
Introduction: Hepatic transarterial chemoembolization is a widely used technique for the treatment o...
BACKGROUND Transarterial chemoembolization (TACE) in patients with hepatocellular cancer (HCC) on...
To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (c...
Objective: This study aimed to explore the risk factors of hepatocellular carcinoma (HCC) and surviv...
Background: To evaluate the safety and efficacy of transjugular intrahepatic portosystemic shunt (TI...
Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently cause...
Background: An association between Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) and the dev...
Purpose: To determine any differences in patient characteristics and outcomes after transarterial ch...
Background: Liver cancer is the second most common cause of cancer-related death, with hepatocellula...
IntroductionThe outcomes of transjugular intrahepatic portosystemic shunt (TIPS) placement in patien...